Streetbeat News

CGON

Cg Oncology Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

27.75

Mkt cap

2B

Volume

321K

High

28.08

P/E Ratio

-1.69

52-wk high

47.78

Low

26.66

Div yield

N/A

52-wk low

25.77

Wall Street analysts suggest a potential 123.3% upside for CG Oncology, Inc. (CGON), driven by positive earnings estimate revisions.

Portfolio Pulse from

January 16, 2025 | 4:15 pm

CG Oncology, Inc. (Nasdaq: CGON) has successfully closed its public offering of 9.2 million shares, including the full exercise of the underwriters' option to purchase additional shares, at $28.00 per share.

Portfolio Pulse from

December 16, 2024 | 9:30 pm

CG Oncology, Inc. announced positive phase 3 results for Cretostimogene in treating BCG-unresponsive NMIBC, with plans to expand its use and potentially file a BLA. The therapy shows increased efficacy when combined with KEYTRUDA.

Portfolio Pulse from

December 13, 2024 | 7:30 pm

CG Oncology, Inc. has announced the pricing of its public offering of 8 million shares at $28.00 per share. The offering includes 7.3 million shares from the company and 700,000 shares from an existing stockholder.

Portfolio Pulse from

December 13, 2024 | 1:30 am

Top Wall Street analysts initiated coverage on several companies with bullish ratings. Notable initiations include WidePoint Corporation, Syndax Pharmaceuticals, Sempra, Tenax Therapeutics, and CG Oncology, all receiving Buy or Outperform ratings with significant price targets.

Portfolio Pulse from Avi Kapoor

October 24, 2024 | 11:40 am

UBS analyst David Dai has initiated coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:26 am

B of A Securities analyst Charlie Yang has reiterated a Buy rating for CG Oncology (NASDAQ:CGON) with a maintained price target of $65.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:41 pm

RBC Capital has initiated coverage on CG Oncology with an Outperform rating and set a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:08 am

HC Wainwright & Co. has reiterated its Buy rating for CG Oncology (NASDAQ:CGON) and maintained a price target of $75, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:44 am

Roth MKM has initiated coverage on CG Oncology with a Buy rating and set a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.